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Detection of In Utero Marijuana Exposure Using Umbilical Cord Tissue by LC-MS/MS
Background:
In utero exposure to marijuana may cause various short-and long-term health problems, such as low birth weight and neonatal withdrawal syndrome. Detection of in utero marijuana exposure with a relatively new specimen type, umbilical cord tissue, can be used to guide social management and treatment. In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed to identify four marijuana metabolites in umbilical cord tissue: tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC (THCA), cannabinol (CBN), and 11-hydroxy-THC (11-OH-THC).
Methods: Approximately 80 residual patient samples that had been previously tested negative for marijuana metabolites were deidentified and pooled to generate drug-free blank. Intra-and interrun precision, accuracy, linearity, sensitivity, carryover, analytical recovery, matrix effect, and specificity were evaluated using drug-free blank spiked with undeuterated and deuterated standards. Each sample (1.00 ± 0.1 g) was weighted and homogenized followed by base hydrolysis and solid phase extraction. Samples were then subjected to LC-MS/MS analysis (AB Sciex Triple Quad 5500 [SCIEX, Framingham, MA] interfaced with Agilent 1260 HPLC [Santa Clara, CA]). Fortyfive umbilical cord tissues that had been previously tested by ELISA (Immunalysis [Pomona, CA]; cutoff 1 ng/g) were reanalyzed by LC-MS/MS. These residual specimens were classified into five groups based on ELISA signals: high positive (>150% calibrator, n = 9), positive (100%-150% calibrator, n = 10), low positive (50%-100% calibrator, n = 9), and indeterminate (50% calibrator-negative control, n = 10), negative (< negative control, n = 7). Results: Calibration curves were reproducible and linear (r > .995) for each analyte in the range of 50 pg/g (LLOQ) and 60 ng/g (ULOQ). Within-run (n = 9) and between-run (n = 27) CVs ranged 1%-4% and 3%-8%, respectively. No interfering substances were identified, and no carryover was observed immediately after a sample containing 60 ng/g. The recovery observed for the four analytes was 55% ± 20%. Regarding the method comparison, the majority of results from LC-MS/MS were consistent with the findings from ELISA. For high positive specimens, 55% specimens (n = 4) were positive for all four analytes, with THCA exhibiting the highest concentrations (1.5-11.3 ng/g); for positive specimens, 20% of specimens (n = 2) were positive for all four analytes and, similarly, THCA showed the highest concentrations ranging from 0.6 ng/g to 9.5 ng/g. For low positive specimens, we found that concentrations of THCA were slightly lower than those in high positive and positive specimens (0.8 ng/g to 6.5 ng/g). Four out of ten indeterminate specimens were positive for at least one analyte. We also found that two out of seven specimens negative by ELISA were positive by LC-MS/MS for CBN with concentrations of 78.4 pg/g and 76.5 pg/g, respectively. Conclusion: The presented method was acceptable for the assessment of in utero marijuana exposure providing quantitative results for four marijuana metabolites.
Institutional Adherence to CDC Guidelines for Hepatitis C Virus Screening Reveals Added Utility of Confirmatory Molecular Testing
Paul Lee, Satoru Kudose, Ronald Jackups, Neil Anderson;Washington University, St Louis, MO Introduction: Current Centers for Disease Control and Prevention (CDC) recommendations for hepatitis C virus (HCV) screening include confirmation of reactive HCV antibody (HCVAB) results for all patients and confirmation of nonreactive results for patients who may have been exposed within the past six months. Our aim was to assess adherence to these recommendations at a 1,250-bed tertiary care hospital in the Midwestern United States. In cases for which confirmatory testing was performed, our secondary aim was to determine the accuracy of the HCVAB screen for the assessment of active HCV infection. Methods: We retrospectively identified consecutive HCVAB samples tested by the ADVIA Centaur Immunoassay System over a period of seven years (January 2010 to December 2016) and by the COBAS AmpliPrep/COBAS TaqMan HCV RNA viral load assay (HCVRNA) over the same time period. The HCVAB test results were recorded as well as the percentage of reactive and nonreactive results that received confirmatory testing within 30 days. When both tests were performed, we calculated the concordance rates. Using the HCVRNA as the gold standard, we calculated the positive predictive values (PPVs) and negative predictive values (NPVs) of the HCVAB for the detection of active HCV disease within the patient population receiving both tests within
